SCHEMBL734433

SCHEMBL734433

CC(=O)C1=C(C(=O)O)CCC(C)C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.35
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
USP2 O75604 1/20 0.33
TLR4 O00206 1/20 0.32
TP53 P04637 1/20 0.31
FABP4 P15090 4/20 0.31
FABP5 Q01469 4/20 0.31
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
CES2 O00748 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TNF P01375 1/20 0.30
NOD1 Q9Y239 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4620598 0.90 HCAR2 (0.37) HCAR2KMT2AALDH1A1KDM4EMAPT
SCHEMBL2646503 0.79 MEN1 (0.38) HCAR2KMT2AALDH1A1KDM4EMAPT
SCHEMBL6759519 0.78 HCAR2 (0.36) HCAR2KMT2AALDH1A1KDM4EMAPT
SCHEMBL8680389 0.77 HCAR2 (0.34) HCAR2KMT2AALDH1A1KDM4EMAPT
SCHEMBL24228647 0.76 HCAR2 (0.35) HCAR2KMT2AALDH1A1KDM4EMAPT
SCHEMBL24228671 0.76 TNF (0.35) HCAR2KMT2AALDH1A1KDM4EMAPT
SCHEMBL7950768 0.73 ALDH1A1 (0.39) HCAR2KMT2AALDH1A1KDM4EMAPT
SCHEMBL7977219 0.73 CRBN (0.38) HCAR2ALDH1A1KDM4EHSD17B10USP2
SCHEMBL8060250 0.73 FFAR3 (0.33) ALDH1A1
SCHEMBL13072044 0.71 ALDH1A1 (0.34) ALDH1A1KDM4EMAPTHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658211-B2 Polyconjugates for in vivo delivery of polynucleotides Arrowhead Madison Inc. (US) 2014-02-25 US disclosed
US-8658211-B2 Polyconjugates for in vivo delivery of polynucleotides Arrowhead Madison Inc. (US) 2014-02-25 US disclosed
US-20120230938-A1 Polyconjugates for In Vivo Delivery of Polynucleotides Arrowhead Madison Inc. (US) 2012-09-13 US disclosed
US-8137695-B2 Transferring interfering RNA sequences into cells via conjugation with physiologically labile bond associated with polyamine and/or polyvinyl ether Arrowhead Madison Inc. (US) 2012-03-20 US disclosed
US-8138383-B2 For cellular delivery; heterogeneity polymer containing cationic groups and hydrophobic groups Arrowhead Madison Inc. (US) 2012-03-20 US disclosed
US-8017109-B2 Cellular deivery, random polyacrylate with multiple hydrophobic monomer ROCHE MADISON INC. (US) 2011-09-13 US disclosed
US-8008355-B2 Delivering nucleic acids to cells; copolymer containing amine monomer and hydrophobic segments ROCHE MADISON INC. (US) 2011-08-30 US disclosed
US-7985406-B2 For cellular delivery; heteropolymer containing amine containing monomer and hydrophobic monomers ROCHE MADISON INC. (US) 2011-07-26 US disclosed
US-20090048410-A1 Membrane Active Heteropolymers Arrowhead Pharmaceuticals, Inc. 2009-02-19 US disclosed
US-20090023890-A1 Membrane Active Heteropolymers Arrowhead Pharmaceuticals, Inc. 2009-01-22 US disclosed
US-20080287630-A1 Endosomolytic Poly(Acrylate) Polymers Arrowhead Pharmaceuticals, Inc. 2008-11-20 US disclosed
US-20080287628-A1 Endosomolytic Poly(Vinyl Ether) Polymers Arrowhead Madison Inc. 2008-11-20 US disclosed
US-20080281044-A1 Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers ROCHE MADISON INC. 2008-11-13 US disclosed
US-20080281041-A1 Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol Arrowhead Madison Inc. 2008-11-13 US disclosed
US-20080269450-A1 Endosomolytic Poly-Beta-Aminoester Polymers ROCHE MADISON INC. 2008-10-30 US disclosed
US-20080152661-A1 Polyconjugates for In Vivo Delivery of Polynucleotides Arrowhead Pharmaceuticals, Inc. 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120230938-A1 Polyconjugates for In Vivo Delivery of Polynucleotides PHAX, NCL, PCBP1 HCAR2 3649/4885KMT2A 4050/4885ALDH1A1 4805/4885
US-20080152661-A1 Polyconjugates for In Vivo Delivery of Polynucleotides PHAX, PCBP1, NCL HCAR2 3573/4885KMT2A 4125/4885ALDH1A1 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.